Tissue distribution and macromolecular binding of extremely low doses of [14C]-benzene in B6C3F1 mice.

The tissue distribution and macromolecular binding of benzene was studied over a dose range spanning nine-orders of magnitude to determine the nature of the dose-response and to establish benzene's internal dosimetry at doses encompassing human environmental exposures. [14C]-Benzene was administered to B6C3F1 male mice at doses ranging between 700 pg/kg and 500 mg/kg body wt. Tissues, DNA and protein were analyzed for [14C]-benzene content between 0 and 48 h post-exposure (625 Ng/kg and 5 microg/kg dose) by accelerator mass spectrometry (AMS). [14C]-Benzene levels were highest in the liver and peaked within 0.5 h of exposure. Liver DNA adduct levels peaked at 0.5 h, in contrast to bone marrow DNA adduct levels, which peaked at 12-24 h. Dose-response assessments at 1 h showed that adducts and tissue available doses increased linearly with administered dose up to doses of 16 mg/kg body wt. Tissue available doses and liver protein adducts plateau above the 16 mg/kg dose. Furthermore, a larger percentage of the available dose in bone marrow bound to DNA relative to liver. Protein adduct levels were 9- to 43-fold greater than DNA adduct levels. These data show that benzene is bioavailable at human-relevant doses and that DNA and protein adduct formation is linear with dose over a dose range spanning eight orders of magnitude. Finally, these data show that the dose of bioactive metabolites is greater to the bone marrow than the liver and suggests that protein adducts may contribute to benzene's hematoxicity.

[1]  J. Vogel.  Rapid Production of Graphite Without Contamination for Biomedical AMS , 1992, Radiocarbon.

[2]  S. Parodi,et al.  Benzene adducts with rat nucleic acids and proteins: dose-response relationship after treatment in vivo. , 1989, Environmental health perspectives.

[3]  Luoping Zhang,et al.  Detection of 1,2,4-benzenetriol induced aneuploidy and microtubule disruption by fluorescence in situ hybridization and immunocytochemistry. , 1994, Mutation research.

[4]  B. Conti,et al.  Benzene, an experimental multipotential carcinogen: results of the long-term bioassays performed at the Bologna Institute of Oncology. , 1989, Environmental health perspectives.

[5]  W. Bodell,et al.  Synthesis of N2-(4-hydroxyphenyl)-2'-deoxyguanosine 3'-phosphate: comparison by 32P-postlabeling with the DNA adduct formed in HL-60 cells treated with hydroquinone. , 1996, Chemical research in toxicology.

[6]  R Snyder,et al.  A perspective on benzene leukemogenesis. , 1994, Critical reviews in toxicology.

[7]  L S Birnbaum,et al.  Effect of exposure concentration, exposure rate, and route of administration on metabolism of benzene by F344 rats and B6C3F1 mice. , 1989, Toxicology and applied pharmacology.

[8]  F P Perera,et al.  Molecular epidemiology and carcinogen-DNA adduct detection: new approaches to studies of human cancer causation. , 1982, Journal of chronic diseases.

[9]  C. Travis,et al.  Protein Binding of Benzene under Ambient Exposure Conditions , 1985, Toxicology and industrial health.

[10]  J. Southon,et al.  Accelerator mass spectrometry in biomedical dosimetry: relationship between low-level exposure and covalent binding of heterocyclic amine carcinogens to DNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R D Irons,et al.  Benzene disposition in the rat after exposure by inhalation. , 1979, Toxicology and applied pharmacology.

[12]  C. Mackerer,et al.  32P analysis of DNA adducts in tissues of benzene-treated rats. , 1989, Environmental health perspectives.

[13]  B. J. Dean.  Recent findings on the genetic toxicology of benzene, toluene, xylenes and phenols. , 1985, Mutation research.

[14]  S. Rappaport,et al.  Comparison of protein adducts of benzene oxide and benzoquinone in the blood and bone marrow of rats and mice exposed to [14C/13C6]benzene. , 1994, Cancer research.

[15]  D. N. Pathak,et al.  Investigation of the DNA adducts formed in B6C3F1 mice treated with benzene: implications for molecular dosimetry. , 1996, Environmental health perspectives.

[16]  K. Turteltaub,et al.  Dose-response studies of MeIQx in rat liver and liver DNA at low doses. , 1995, Carcinogenesis.

[17]  S. Rappaport,et al.  Production of benzoquinone adducts with hemoglobin and bone-marrow proteins following administration of [13C6]benzene to rats. , 1993, Carcinogenesis.

[18]  K. Turteltaub,et al.  Studies on DNA adduction with heterocyclic amines by accelerator mass spectrometry: a new technique for tracing isotope-labelled DNA adduction. , 1993, IARC scientific publications.

[19]  R Snyder,et al.  Partial hepatectomy reduces both metabolism and toxicity of benzene. , 1979, Journal of toxicology and environmental health.

[20]  K. Turteltaub,et al.  Applications of Accelerator Mass Spectrometry in Toxicology: A Highly Sensitive Tool for Low-Level Isotope Measurements , 1996 .

[21]  J. Barrett,et al.  Chemically induced aneuploidy in mammalian cells: mechanisms and biological significance in cancer. , 1986, Environmental mutagenesis.

[22]  Martyn T. Smith,et al.  Characterization of micronuclei induced in human lymphocytes by benzene metabolites. , 1990, Cancer research.

[23]  F. Beland,et al.  DNA adduct measurements and tumor incidence during chronic carcinogen exposure in animal models: implications for DNA adduct-based human cancer risk assessment. , 1992, Chemical research in toxicology.

[24]  D. N. Pathak,et al.  DNA adduct formation in the bone marrow of B6C3F1 mice treated with benzene. , 1995, Carcinogenesis.